Posted by Michael Wonder on 12 Apr 2023
Kala Pharmaceuticals receives FDA fast track designation for KPI-012, a human MSC-S therapy for persistent corneal epithelial defect
12 April 2023 - Kala Pharmaceuticals today announced that the US FDA has granted fast track designation for Kala’s human mesenchymal stem cell secretome therapy (KPI-012) for the treatment of persistent corneal epithelial defect, a rare and debilitating ocular condition.
In February 2023, Kala dosed the first patient in its CHASE (Corneal Healing After SEcretome therapy) Phase 2b trial evaluating KPI-012 for the treatment of persistent corneal epithelial defect.
